Definium Therapeutics
Develops psychedelic-derived medicines for people with psychiatric and neurodevelopmental disorders
Highlights
- New on EvolcAdded 2026-11-13
About Definium Therapeutics
Definium Therapeutics is a clinical-stage biotechnology company developing psychedelic-derived treatments for brain health disorders. Its pipeline includes DT120 ODT, a lysergide formulation being studied for anxiety, depression and PTSD, and DT402, an R-enantiomer of MDMA being developed for autism spectrum disorder.
The company works with patients, providers and regulators and develops medicines through clinical research. It was founded in 2019 as MindMed and began trading under the Definium Therapeutics name in 2026. Its workforce is remote-first, and listed openings include roles in clinical operations, commercial, medical affairs, finance and quality.
Product: Clinical development of DT120 ODT, a lysergide formulation, and DT402, an R-enantiomer of MDMA.
Jobs at Definium Therapeutics
More biotech & pharma companies
Disc Medicine
Clinical-stage biopharma developing first-in-class therapies for hematologic disorders, from rare blood diseases to chronic conditionsNew on EvolcDrug Hunter
Drug discovery intelligence and research tools for pharmaceutical scientists, drug discovery teams and investorsRemote-friendlyDyne Therapeutics
Targeted genetic therapies for people with genetically driven neuromuscular diseasesNew on EvolcDyno Therapeutics
AI-enabled genetic technology development for biotechnology and medicine developersNew on EvolcEarli
Develops genetic switches that activate in cancer cells for cancer detection and therapeutic applicationsNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content delivery
- CloudflareHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Website resourcedeclared script/iframe or software asset
Content management
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- ReactHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Privacy & consent
- CookieYesHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Recruiting
- GreenhouseMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Page markupsoftware structure signature
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.